Consistent with basal B PDXs, the TIC/EMT high patient group was enriched for co-expression of FGFR1 and HGF. Importantly, we found that co-expression of HGF and FGFR1 predicts poor relapse-free survival specifically among basal breast cancers, providing further support that FGFR1 and MET pathways contribute to the tumourigenicity of highly mesenchymal breast cancers. This evidence concerns the gene MET and breast carcinoma.